RECURRENT RENAL CELL CARCINOMA
Clinical trials for RECURRENT RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to starve and attack tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…
Matched conditions: RECURRENT RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…
Matched conditions: RECURRENT RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Could a two-drug combo slow kidney cancer better than one?
Disease control OngoingThis study tests whether adding an experimental immune-boosting drug (anti-OX40 antibody) to the standard targeted therapy axitinib helps control advanced kidney cancer better than axitinib alone. About 62 adults whose cancer worsened after prior immunotherapy will receive either…
Matched conditions: RECURRENT RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New test could spot kidney cancer early using blood and urine
Diagnosis OngoingThis study looks at whether measuring certain immune cells (MDSCs) in blood and urine can help detect kidney cancer early and monitor how it responds to treatment. Researchers will compare MDSC levels in healthy volunteers, patients with early-stage kidney cancer, and those with …
Matched conditions: RECURRENT RENAL CELL CARCINOMA
Sponsor: University of Southern California • Aim: Diagnosis
Last updated May 15, 2026 11:55 UTC